← All trials
NCT07143227
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Dec 31, 2026
- First posted
- Aug 27, 2025
- Last posted
- Sep 12, 2025
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sciwind Biosciences APAC CO Pty. Ltd.Lead sponsor
- Shandong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.